Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets
Aurinia has announced a 45% workforce reduction to bolster sales of the lupus drug Lupkynis and advance the development of AUR200.
Aurinia has announced a 45% workforce reduction to bolster sales of the lupus drug Lupkynis and advance the development of AUR200.
What's Your Reaction?
